Results 141 to 150 of about 215,011 (302)
Organoid Brain‐Machine‐Interface Devices for Central Nervous System Repair
We envision organoid brain‐machine‐interface (Organoid‐BMI) devices as new biohybrid bidirectional communication pathways to connect the human CNS and the external world for personalized CNS repair and regeneration. ABSTRACT Central nervous system (CNS) repair and regeneration suffer from tremendous clinical challenges due to current limitations in ...
Yantao Xing +10 more
wiley +1 more source
This study develops an intelligent NIR‐II‐responsive nanoplatform to combat immunosuppression in breast cancer. It enables real‐time visualization of macrophage activity via “off‐on” fluorescence while simultaneously reprogramming macrophages through the CSF‐1R and CD47‐SIRPα pathways.
Yingbo Li +14 more
wiley +1 more source
Tanino Y, Nishioka K, Yamamoto C, et al. Infect Drug Resist. 2024:17:531–541. Our authors have advised that there are two sentences that needed revision in the abstract section of the published paper.
Tanino Y +18 more
doaj
This study presents an ultrasound‐responsive nanoplatform, CS‐BT@MZ@NEs, with a BaTiO3/Mn‐Zif‐8 core and a chondroitin sulfate coating for Golgi targeting. By leveraging neutrophil hitchhiking, it enables targeted delivery to infection sites. Under ultrasound stimulation, CS‐BT@MZ@NEs generates ROS and modulates Golgi pH to activate cGAS–STING ...
Shicheng Huo +7 more
wiley +1 more source
The impact of triple drug immunosuppression on clinical results of cadaveric kidney transplantation: a comparison of conventional immunosuppression. [PDF]
A retrospective study was carried out in 110 cadaveric kidney transplant recipients to compare the effects of low doses of cyclosporine (CsA), azathioprine (AZP) and steroids (triple-drug therapy) with those of higher doses of steroids plus AZP ...
Tanaka, Shinichiro +13 more
core
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy [PDF]
Blockade of PD-1 immunosuppression boosts CAR T-cell ...
Phillip K Darcy (13533889) +2 more
core
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng +5 more
wiley +1 more source
Tumor‐Infiltrating mregDCs Restrain Anti‐Tumor Immunity in Early Relapse HCC
Tumor‐infiltrating mregDCs are regulated by the TNFR2‐non‐canonical NF‐κB axis, which is mediated by TNF‐α secreted by CD161+CD8+ T cells. These mregDCs recruit CD161+CD8+ T cells via the CCL20‐CCR6 axis, forming a positive feedback loop that enhances immunosuppression, promotes early recurrence of HCC, and further confirms TNFR2 as a key therapeutic ...
Zefan Zhang +13 more
wiley +1 more source
PLD3 activates the lysosomal‐AKT‐NF‐κB axis to drive cellular senescence in macrophages, establishing an immunosuppressive TME by limiting the infiltration of cytotoxic T, NK, and NKT cells, which confers resistance to anti‐PD‐1 therapy. Abrine inhibits PLD3 expression, restoring antitumor immunity and synergizing with anti‐PD‐1 treatment.
Xingtu Qin +11 more
wiley +1 more source
BackgroundPharmacologic immunosuppression regimes are commonly employed in stem cell clinical trials to mitigate host immune rejection and promote survival and viability of transplanted cells.
Shravan Gowrishankar +4 more
doaj +1 more source

